RapidPulse Receives FDA Approval to Begin IDE Study | Read More
New study presented at the Society of Vascular and Interventional Neurology (SVIN) 2024 shows RapidPulse® system delivers 68% First Pass TICI≥2c and 100% Frontline TICI≥2b | Read More
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.